Tracers / [68Ga]AAZTA-FAPI-46
[68Ga]AAZTA-FAPI-46
Also written as [Ga-68]Ga-AAZTA-FAPI-46
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 2
What it is
- Compound class
- AAZTA-conjugated FAP inhibitor (FAPI-46-derived)
- Target / mechanism
- Fibroblast activation protein (FAP) inhibitor targeting FAP-expressing tumor stroma PMID 40762892
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Scintomics GallElut Scintomics | custom manifold | SPE | 84.97 ± 1.37% | greater than 98% | AAZTA-FAPI-46 | 40762892 2025 EJNMMI Radiopharm Chem The preparation of [68Ga]Ga-AAZTA-FAPI-46 was automated on a GallElut+ system (Scintomics, Germany). — The radiochemical yield was 84.97 ± 1.37%. |
| Manual synthesis | — | SPE | — | greater than 98% | AAZTA-FAPI-46 | 40762892 2025 EJNMMI Radiopharm Chem Gallium-68 manual radiolabelling |
Need this precursor?We can point you to suppliers for [68Ga]AAZTA-FAPI-46, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40762892. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40762892: 'AAZTA-FAPI-46'. Stage set/updated at stage 23 from PMID 40762892: 'Preclinical evaluation of [68Ga]Ga-AAZTA-FAPI-46: a novel PET tracer for targeting fibroblast activation protein (FAP).'.